The effects of switching from etelcalcetide to upacicalcet in hemodialysis patients with secondary hyperparathyroidism.

ABSTRACT:

Aims

No English-language research papers have reported on the clinical use of upacicalcet, a novel intravenous calcimimetic agent for the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. Therefore, this study aimed to investigate the outcomes of switching from etelcalcetide to upacicalcet.

Materials and methods

The subjects included 37 hemodialysis patients with SHPT treated with etelcalcetide before switching to upacicalcet. This study was a single-center retrospective study conducted in Japan. Serum levels of corrected calcium (Ca), phosphorus (P), intact parathyroid hormone (iPTH), and the dose of maxacalcitol were assessed at 3 and 6 months after switching to upacicalcet.

Results

As a result of the switch from etelcalcetide to upacicalce

SUBMITTER: Sato E 

PROVIDER: S-EPMC12573280 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature